Literature DB >> 12767526

Association of the genetic polymorphism in cytochrome P450 (CYP) 1A1 with risk of familial prostate cancer in a Japanese population: a case-control study.

Kazuhiro Suzuki1, Hiroshi Matsui, Haruki Nakazato, Hidekazu Koike, Hironobu Okugi, Masaru Hasumi, Nobuaki Ohtake, Seiji Nakata, Tomoyuki Takei, Motoaki Hatori, Kazuto Ito, Hidetoshi Yamanaka.   

Abstract

Association between genetic polymorphisms of CYP1A1 and familial prostate cancer risk was examined by a case-control study of 185 individuals. Although the individual analysis of m1 or m2 genotype of CYP1A1 showed no significant association with prostate cancer risk, the presence of any mutated alleles significantly increased prostate cancer risk in comparison with wild-type genotypes by combination analysis (odds ratio [OR]=2.38; 95% confidence interval [CI]=1.72-3.29; P=0.0069). Furthermore, metastatic cancer had a significant association with mutated alleles of m1 and m2. These finding suggested that CYP1A1 polymorphisms has an association with prostate cancer risk, especially with progression of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12767526     DOI: 10.1016/s0304-3835(03)00182-4

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  8 in total

1.  RETRACTED: Relationship Between Aldosterone Synthase CYP1A1 MspI Gene Polymorphism and Prostate Cancer Risk.

Authors:  Chao Ou; Yan Zhao; Jiang-Hua Liu; Bo Zhu; Pei-Zhang Li; Hui-Liu Zhao
Journal:  Technol Cancer Res Treat       Date:  2016-06-22

2.  Further evidence for null association of phenol sulfotransferase SULT1A1 polymorphism with prostate cancer risk: a case-control study of familial prostate cancer in a Japanese population.

Authors:  Hidekazu Koike; Haruki Nakazato; Nobuaki Ohtake; Hiroshi Matsui; Hironobu Okugi; Yasuhiro Shibata; Seiji Nakata; Hidetoshi Yamanaka; Kazuhiro Suzuki
Journal:  Int Urol Nephrol       Date:  2008-03-27       Impact factor: 2.370

3.  Identification of novel SNPs associated with risk and prognosis in patients with castration-resistant prostate cancer.

Authors:  Tristan M Sissung; John Deeken; Crystal R Leibrand; Douglas K Price; Sheryl Ehrlich; Seth M Steinberg; David J Liewehr; William Dahut; William D Figg
Journal:  Pharmacogenomics       Date:  2016-11-24       Impact factor: 2.533

4.  Quantitative synthesis of the association between the cytochrome P450 1A1 Ile462Val polymorphism and prostate cancer risk.

Authors:  Guangye Han; Yanjuan Ma; Pei Liu; Xiaoxia Wei; Xinjun Zhang; Feng Zhu
Journal:  Tumour Biol       Date:  2013-02-06

5.  Association of CYP1A1 polymorphisms with prostate cancer risk: an updated meta-analysis.

Authors:  Huawen Li; Deqian Xiao; Liren Hu; Taiping He
Journal:  Mol Biol Rep       Date:  2012-10-14       Impact factor: 2.316

6.  CYP1A1 MspI polymorphism is associated with prostate cancer susceptibility: evidence from a meta-analysis.

Authors:  Gang Ding; Weiguo Xu; Hedai Liu; Ming Zhang; Qian Huang; Zhijun Liao
Journal:  Mol Biol Rep       Date:  2013-03-09       Impact factor: 2.316

Review 7.  ESR1 Gene Polymorphisms and Prostate Cancer Risk: A HuGE Review and Meta-Analysis.

Authors:  Yu-Mei Wang; Zu-Wang Liu; Jing-Bo Guo; Xiao-Fang Wang; Xin-Xin Zhao; Xuan Zheng
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

8.  In vivo biochemical and gene expression analyses of the antioxidant activities and hypocholesterolaemic properties of Tamarindus indica fruit pulp extract.

Authors:  Chor Yin Lim; Sarni Mat Junit; Mahmood Ameen Abdulla; Azlina Abdul Aziz
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.